SLC7A11 and metabolic dysfunction-associated steatotic liver disease: Here, we demonstrated that SLC7A11 exerts its mitigating effect on NAFLD through a variety of mechanisms, including the regulation of intracellular Fe2+ and GSH levels, which lead to a reduction in lipid accumulation (Fig. 6A-Z).